In NSCLC, while it was initially reported that the differential Crizotinib sensitivity in EML4-ALK-expressing cells is related to the existence of the four EML4-ALK fusion variants19, results from subsequent studies did not confirm the relationship between these EML4-ALK variants and Crizotinib responses17, 20. This evidence concerns the gene ALK and non-small cell lung carcinoma.